Ibrutinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-IBRUTINIB |
|---|---|
| Type | Drug |
| Aliases | ImbruvicaІбрутиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Bruton's tyrosine kinase (BTK) inhibitor |
|---|---|
| Mechanism | Irreversible covalent inhibitor of BTK; disrupts B-cell receptor signaling, induces apoptosis in malignant B cells. |
| Typical dosing | 560 mg PO once daily (MZL); 420 mg PO once daily (CLL) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Approved for relapsed/refractory MZL after at least one prior anti-CD20 therapy. Not first-line for HCV-MZL but relevant for later lines if antiviral + chemoimmunotherapy fail.
Used By
No reverse references found in the YAML corpus.